Recs

0

Why Aralez Pharmaceuticals Inc. Got Slaughtered Today

What happened

Aralez Pharmaceuticals (NASDAQ: ARLZ  ) was down 30% just before the market closed Monday after it announced disappointing fourth-quarter earnings and lackluster guidance for the year ahead.

So what

Revenue was up substantially from $6 million in the year ago quarter, to $20 million in the recently completed quarter, but that's still lower than investors were expecting given all that's happened with Aralez Pharmaceuticals over the last year. In February 2016, Pozen merged with Tribute Pharmaceuticals Canada to create Aralez Pharmaceuticals, which added about a dozen drugs from Tribute to Pozen's Yosprala as well as Vimovo and Treximet, which are marketed by its partner. Within the last year, Aralez Pharmaceuticals also acquired two other drugs, Zontivity and Toprol-XL, the latter of which included an authorized generic (AG).

Pills on top of paper money.

Image source: Getty Images.

But sales of the additions are nothing to get too excited about. Tribute added $6.4 million during the quarter; Toprol-XL, the AG of Troprol-XL, and Zontivity added $8.6 million combined, although the deal for Toprol-XL didn't close until the end of October, so it was really only two months of sales. Sales of Yosprala, which was launched in October, weren't broken out in the press release, suggesting the sales are likely pretty low.

For this year, management guided for revenue between $80 million and $100 million. The low end of that guidance is equal to the run rate coming out of the fourth quarter, suggesting there's potential minimal growth over the next year.

Now what

Management might be sandbagging, giving guidance that it knows it can hit, but if that's the case, it should have done what many companies do and just refused to give revenue guidance because the launch of Yosprala is too hard to predict.

Aralez Pharmaceuticals could be a good value at this knocked-down price, but cautious investors will want to wait until management can show that it can consistently grow revenue each quarter before investing.

10 stocks we like better than Aralez Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Aralez Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 6, 2017


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 4008151, ~/Articles/ArticleHandler.aspx, 3/25/2017 1:45:13 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
Change down DOW 20596.7 -59.9 -0.3%
Change down S&P 500 2344.0 -2.0 -0.1%
Change up NASD 5828.7 11.0 0.2%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

3/24/2017 4:00 PM
ARLZ $2.19 Down -0.04 -1.79%
Aralez Pharmaceuti… CAPS Rating: **

Advertisement